Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute


Results of the SORAYA Study Show Conjugate Therapy Produced Remissions in One-third of Patients With Drug-Resistant Ovarian Cancer

February 10, 2023

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

Immunotherapy Propels Urothelial Carcinoma Treatment Advances

February 02, 2023

Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.

Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC

February 01, 2023

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.

Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows

February 01, 2023

A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30, 2023

Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.

Novel Combinations Promote Individualized Care in Bladder and Prostate Cancer

January 24, 2023

Alicia Morgans, MD, MPH, discussed the evolving role of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, investigational immunotherapy combinations in urothelial cancer, and how antibody-drug conjugates provide a unique means of delivering toxic agents directly to tumors.

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16, 2023

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.

x